Pramlintide Acetate Injection (SymlinPen 120, SymlinPen 60) shortage
Possibly permanent — AstraZeneca AB, the only company we could find that sells pramlintide acetate injections, has told the FDA it is discontinuing its product as of Oct 6, 2026. The FDA lists this under “To be discontinued”. We could not find another company that sells the same medicine, so talk with your prescriber about a long-term plan before your supply runs out.
AstraZeneca is stopping production of Symlin (pramlintide acetate) injection, and this change may be permanent. No other manufacturers are listed as a source for this medicine right now.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is pramlintide acetate still in shortage? — status as of Oct 6, 2026
Still listed as “To be discontinued” as of Oct 6, 2026. We could not find another company that sells pramlintide acetate injections, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; we could not confirm another company listing it (see below).
Shortage timeline
-
Oct 27, 2025Currently in shortage2 of 2 products affected.
-
Oct 27, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which pramlintide acetate products are affected — by company
Company: AstraZeneca AB 📞 800-236-9933 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | SymlinPen® 60 Injection, 1000 ug/mL | 1000 ug/mL | — | Discontinuation of the manufacture of the drug. | — |
| To Be Discontinued | SymlinPen® 120 Injection, 1000 ug/mL | 1000 ug/mL | — | Discontinuation of the manufacture of the drug. | — |
These rows are company reports to the FDA for Pramlintide Acetate Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock.
Why is AstraZeneca AB discontinuing pramlintide acetate?
AstraZeneca AB has reported to the FDA that it is permanently stopping the manufacture of two of its pramlintide acetate injection products — the SymlinPen® 60 and the SymlinPen® 120, both in the 1000 mcg/1 mL strength. That's why these specific products appear on the shortage list.
AstraZeneca did not share a specific public reason for why they are stopping production of these two pens. It's worth knowing that this report reflects only what AstraZeneca AB has filed with the FDA — it speaks only to their products and their decision, not to what other manufacturers may or may not have available.
Based on the company-reported reason(s) and notes on file with the FDA for Pramlintide Acetate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take pramlintide acetate?
Pramlintide Acetate Injection (the SymlinPen pen) is currently on the FDA shortage list, and I want to walk you through what that means for you.
The one strength on this record, 1000 ug/1 mL — covering both SymlinPen 60 and SymlinPen 120 — has no available source reported right now. There is no other strength listed that still has supply.
The reason given is that the manufacturer, AstraZeneca, is discontinuing production of this medicine. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, and no estimated-recovery date is listed. At this time, no other maker of this exact medicine appears in our records.
Here is what I suggest you do:
- Do not stop, skip, or change your doses on your own — keep taking it as prescribed while you sort out next steps.
- Since this product is being discontinued, please talk with your prescriber or pharmacist soon about a clinician-chosen plan going forward.
- Manufacturer contact information is listed on this page for reference, though pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. Your prescriber can help you find the right path for your situation.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 2 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| SymlinPen 1000 ug/mL | AstraZeneca | 2 cartridges | $217.521 | — | Availability likely |
| SymlinPen 1000 ug/mL | AstraZeneca | 2 cartridges | $330.952 | — | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Codes & classification for pharmacists and billers
Where does this data come from?
Other endocrinology/metabolism shortages
Pramlintide acetate shortage FAQs
Is pramlintide acetate still in shortage?
Which strengths of pramlintide acetate are affected?
Which pramlintide acetate products are affected?
When will pramlintide acetate be available again?
Is the brand or the generic affected?
What should I do if I take pramlintide acetate?
Still have a question about the pramlintide acetate shortage?
Ask a pharmacist about this shortage →View Pramlintide Acetate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.